Skip to content
Screener

Twist Bioscience Corporation TWST Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Azenta logo
AzentaAZTA
$1.22M-24.0%
Agilent Technologies logo
Agilent TechnologiesA
$1M0.0%
Illumina logo
IlluminaILMN
$24M-11.1%
10x Genomics, Inc. logo
10x Genomics, Inc.TXG
$3.02M-14.4%
GeneDx Holdings logo
GeneDx HoldingsWGS
$476K
Personalis, Inc. logo
Personalis, Inc.PSNL
$20.95M+17.8%

Other financials

Income statement

See full
Revenue$110.7M+19.3%
Gross profit$57.1M+24.1%
Operating income-$45.9M-10.4%
Net income-$44.0M-11.9%
EPS (diluted)-$0.71-7.6%

Balance sheet

See full
Cash & equivalents$124.9M-41.4%
Total debt$110.8M+16.3%
Total equity$455.1M+3.4%
Total assets$676.2M+13.5%

Cash flow

See full
Operating cash flow-$17.6M-35.2%
CapEx$7.9M+90.3%
Free cash flow-$25.4M-48.5%

Valuation

See full
Market cap$7.21B+361%
Enterprise value$7.2B+396%
P/S17.6×+13.3×

Profitability

See full
Gross margin52.1%+5.4pp
Operating margin-33.9%-9.9pp
Net margin-19.8%-7.7pp
FCF margin-23.2%+7.0pp

Returns & leverage

See full
Return on equity-18.2%-6.3pp
Debt / equity0.2×0.0×
Current ratio2.7×-1.8×

Where this comes from

Reported directly by Twist Bioscience Corporation in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.

The source filing: Twist Bioscience Corporation’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:28 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q1 2026
Accession
0001581280-26-000040
(in thousands)Six months ended March 31, 2026Six months ended March 31, 2025
Cash paid for investment in equity securities(1)
Net cash used in investing activities$(22,639)$(2,962)
Financing activities
Proceeds from exercise of stock options$2,089$3,722
Proceeds from the issuance of liability related to sale of future revenue15,000
Proceeds from issuance under employee stock purchase plan2,3572,429
Repurchases of common stock for income tax withholding(10)(11)
Net cash provided by financing activities$4,436$21,140

Item 1. Financial Statements (unaudited)

FAQ

What is Twist Bioscience Corporation's stock issuance proceeds?
Twist Bioscience Corporation (TWST) reported stock issuance proceeds of $1.79M in Q1 2026.
How has Twist Bioscience Corporation's stock issuance proceeds changed year-over-year?
Twist Bioscience Corporation's stock issuance proceeds increased by 131.7% year-over-year, from $772K to $1.79M.
What is the long-term trend for Twist Bioscience Corporation's stock issuance proceeds?
Over 4 years (2021 to 2025), Twist Bioscience Corporation's stock issuance proceeds has grown at a -10.5% compound annual growth rate (CAGR), from $14.56M to $9.34M.
What does stock issuance proceeds mean?
Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Ask your AI about Twist Bioscience Corporation's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude